[Asia Economy Reporter Ji Yeon-jin] Bio-pharmaceutical company Naturecell announced on the 3rd that the Ministry of Food and Drug Safety rejected the domestic Phase 1/2a clinical trial plan to explore the safety and efficacy of the allogeneic adipose-derived mesenchymal stem cell therapy AstroStem-V in pneumonia patients caused by COVID-19 infection.
The company explained, "We received a request from the Ministry of Food and Drug Safety to supplement the data for the clinical trial plan of AstroStem-V, and we prepared and submitted the related materials, but it was rejected due to insufficient data on some items."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
